Standard BioTools Inc (NASDAQ:LAB) has a beta value of 1.63 and has seen 1.01 million shares traded in the last trading session. The company, currently valued at $481.31M, closed the last trade at $1.27 per share which meant it gained $0.08 on the day or 6.72% during that session. The LAB stock price is -115.75% off its 52-week high price of $2.74 and 23.62% above the 52-week low of $0.97. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.12 million shares traded. The 3-month trading volume is 1.79 million shares.
The consensus among analysts is that Standard BioTools Inc (LAB) is Buy stock at the moment, with a recommendation rating of 1.67. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.04.
Standard BioTools Inc (NASDAQ:LAB) trade information
Over the past 30 days, the shares of Standard BioTools Inc (NASDAQ:LAB) have changed 4.96%. Short interest in the company has seen 17.68 million shares shorted with days to cover at 9.06.
Wall Street analysts have a consensus price target for the stock at $3.25, which means that the shares’ value could jump 60.92% from current levels. The projected low price target is $3.25 while the price target rests at a high of $3.25. In that case, then, we find that the current price level is -155.91% off the targeted high while a plunge would see the stock gain -155.91% from current levels.
Standard BioTools Inc (LAB) estimates and forecasts
The company’s shares have lost -29.44% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -3.00%.
3 analysts offering their estimates for the company have set an average revenue estimate of 40.1M for the current quarter. 3 have an estimated revenue figure of 39.23M for the next ending quarter. Year-ago sales stood 45.54M and 37.2M respectively for this quarter and the next, and analysts expect sales will shrink by -11.95% for the current quarter and -3.00% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 11.61% over the past 5 years. Earnings growth for 2025 is a modest 65.38% while over the next 5 years, the company’s earnings are expected to increase by 57.47%.
LAB Dividends
Standard BioTools Inc is expected to release its next earnings report on 2025-Feb-25 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Standard BioTools Inc (NASDAQ:LAB)’s Major holders
Insiders own 1.86% of the company shares, while shares held by institutions stand at 73.11% with a share float percentage of 74.49%. Investors are also buoyed by the number of investors in a company, with Standard BioTools Inc having a total of 185.0 institutions that hold shares in the company. The top two institutional holders are CASDIN CAPITAL, LLC with over 63.96 million shares worth more than $113.21 million. As of 2024-06-30, CASDIN CAPITAL, LLC held 17.1782% of shares outstanding.
The other major institutional holder is VIKING GLOBAL INVESTORS LP, with the holding of over 58.65 million shares as of 2024-06-30. The firm’s total holdings are worth over $103.81 million and represent 15.7524% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Dec 31, 2024 , the former fund manager holds about 2.42% shares in the company for having 9.17 shares of worth $11.65 million while later fund manager owns 7.72 shares of worth $9.8 million as of Mar 31, 2025 , which makes it owner of about 2.04% of company’s outstanding stock.
